McAloon Christopher J, Theodoreson Mark D, Hayat Sajad, Osman Faizel
Cardiology Research Fellow, Department of Cardiology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry CV2 2DX and Translational & Experimental Medicine, University of Warwick Medical School, Coventry.
Core Medical Trainee Year One, Department of Cardiology, University Hospitals Bristol NHS Trust, Bristol Heart Institute, Bristol.
Br J Hosp Med (Lond). 2017 Jun 2;78(6):312-319. doi: 10.12968/hmed.2017.78.6.312.
The prevalence of heart failure is increasing and it is associated with significant mortality and morbidity. Optimal medical therapy improves outcome, but heart failure continues to have a substantial impact on both the individual patient and wider society. Over the last two decades, cardiac resynchronization therapy has revolutionized the treatment of selected patients who have heart failure. Cardiac resynchronization therapy significantly reduces mortality and hospitalization through reverse cardiac remodelling. This review informs non-specialists about cardiac resynchronization therapy and for which patients it should be considered.
心力衰竭的患病率正在上升，且与显著的死亡率和发病率相关。优化的药物治疗可改善预后，但心力衰竭仍对个体患者和更广泛的社会产生重大影响。在过去二十年中，心脏再同步治疗彻底改变了部分心力衰竭患者的治疗方式。心脏再同步治疗通过逆转心脏重塑显著降低死亡率和住院率。本综述旨在让非专科医生了解心脏再同步治疗以及哪些患者应考虑接受该治疗。
